Boston presented the pair of trial readouts at the 2026 American College of Cardiology (ACC) conference in New Orleans.
The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...
CHAMPION-AF shows Boston Scientific's Watchman FLX as a safe, effective first-line option for stroke risk reduction in ...
Data for Boston Scientific’s Watchman FLX implant met the primary endpoint in a new study. The stock is falling anyway.
Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...
Marian Regional Medical Center has successfully completed its 500th Watchman procedure, a milestone in providing advanced treatment options for patients with atrial fibrillation (AFib). The Watchman ...
Apr. 9—Medical Center Hospital is proud to announce that Dr. Manohar Angirekula, Dr. Adam Farber and Dr. Fernando Boccalandro successfully implanted the first WATCHMAN FLX Pro Device on April 1. MCH ...
MedPage Today on MSN
Watchman LAA occluder bounces back as alternative to OAC in CHAMPION-AF
Study suggests a path forward for device therapy, though caveats are plenty ...
Boston Scientific (BSX) stock tumbled 9% to two-year lows after Watchman trial data revealed stroke concerns and Raymond ...
Shares of medical device company Boston Scientific (NYSE:BSX) fell 9.4% in the afternoon session after Raymond James ...
MedStar Heart & Vascular Institute now offers patients with irregular heart rhythm a minimally invasive option to reduce the risk of stroke, as well as enable stopping long-term use of blood thinning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results